Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.

Synonyms

BCG, Live, Connaught Strain

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Theracys	Injection, powder, lyophilized, for solution	81 mg/3mL	Intravesical	Sanofi Pasteur Limited	2011-07-22	2017-05-20

Categories

UNII

5H5854UBMZ

CAS number

Not Available

Pharmacology

Indication

Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

Associated Conditions

Associated Therapies

Salvage therapy

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Illicit
2-Methoxyethanol	The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental
5-androstenedione	The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Illicit
Abatacept	The risk or severity of adverse effects can be increased when Abatacept is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Abetimus	The risk or severity of adverse effects can be increased when Abetimus is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Abituzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abituzumab.	Investigational
Acteoside	The risk or severity of adverse effects can be increased when Acteoside is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Adalimumab	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Adalimumab.	Approved
Adalimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adalimumab.	Approved
Adecatumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adecatumumab.	Investigational
Adefovir	The risk or severity of adverse effects can be increased when Adefovir is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Aducanumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Aducanumab.	Investigational
Afelimomab	The risk or severity of adverse effects can be increased when Afelimomab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Alclometasone	The risk or severity of adverse effects can be increased when Alclometasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Aldesleukin	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Aldesleukin.	Approved
Aldesleukin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Aldesleukin.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Aldosterone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Investigational
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Withdrawn
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Alicaforsen	The risk or severity of adverse effects can be increased when Alicaforsen is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Alirocumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Alirocumab.	Approved
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Amatuximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amatuximab.	Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Amcinonide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
AMG 108	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with AMG 108.	Investigational
Amikacin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amikacin.	Approved, Investigational, Vet Approved
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Anakinra	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Anakinra.	Approved
Anakinra	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Anakinra.	Approved
Androstenedione	The risk or severity of adverse effects can be increased when Androstenedione is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Anecortave is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
anecortave acetate	The risk or severity of adverse effects can be increased when anecortave acetate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Anifrolumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Anifrolumab.	Investigational
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Apolizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Apolizumab.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ascrinvacumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ascrinvacumab.	Investigational
Asfotase Alfa	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Asfotase Alfa.	Approved, Investigational
Atamestane	The risk or severity of adverse effects can be increased when Atamestane is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Atezolizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Atezolizumab.	Approved, Investigational
AVE9633	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with AVE9633.	Investigational
Avelumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Avelumab.	Approved, Investigational
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Bacitracin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bacitracin.	Approved, Vet Approved
Bapineuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bapineuzumab.	Investigational
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Bavituximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bavituximab.	Investigational
Beclomethasone dipropionate	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Beclomethasone dipropionate.	Approved, Investigational
Beclomethasone dipropionate	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Beclomethasone dipropionate.	Approved, Investigational
Bectumomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bectumomab.	Investigational
Begelomab	The risk or severity of adverse effects can be increased when Begelomab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Investigational
Belatacept	The risk or severity of adverse effects can be increased when Belatacept is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Belimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Belimumab.	Approved
Benznidazole	The risk or severity of adverse effects can be increased when Benznidazole is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Besilesomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Besilesomab.	Approved
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Vet Approved
Bevacizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bevacizumab.	Approved, Investigational
BIIB015	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with BIIB015.	Investigational
Bimagrumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bimagrumab.	Investigational
Bivatuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bivatuzumab.	Investigational
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Blinatumomab	The risk or severity of adverse effects can be increased when Blinatumomab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Blosozumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Blosozumab.	Investigational
Bococizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bococizumab.	Investigational
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Briakinumab	The risk or severity of adverse effects can be increased when Briakinumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Brodalumab	The risk or severity of adverse effects can be increased when Brodalumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Budesonide	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Budesonide.	Approved
Budesonide	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Budesonide.	Approved
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Canakinumab	The risk or severity of adverse effects can be increased when Canakinumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Caplacizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Caplacizumab.	Investigational
Capromab pendetide	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Capromab pendetide.	Approved
Carbamazepine	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Carbamazepine.	Approved, Investigational
Carbamazepine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Carbamazepine.	Approved, Investigational
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Carlumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Carlumab.	Investigational
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental
Catumaxomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Catumaxomab.	Approved, Investigational, Withdrawn
Certolizumab pegol	The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ciprofloxacin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ciprofloxacin.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Cixutumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Cixutumumab.	Investigational
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Clazakizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Clazakizumab.	Investigational
Clenoliximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Clenoliximab.	Investigational
Clindamycin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Clindamycin.	Approved, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Clobetasol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Clobetasone	The risk or severity of adverse effects can be increased when Clobetasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Clocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Coltuximab ravtansine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Coltuximab ravtansine.	Investigational
Conatumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Conatumumab.	Investigational
Concizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Concizumab.	Investigational
Cortexolone 17α-propionate	The risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Corticosterone	The risk or severity of adverse effects can be increased when Corticosterone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental
Corticotropin	The risk or severity of adverse effects can be increased when Corticotropin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Vet Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
CR002	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with CR002.	Investigational
Crenezumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Crenezumab.	Investigational
Crotedumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Crotedumab.	Investigational
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Cyclosporine	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclosporine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Cyclosporine.	Approved, Investigational, Vet Approved
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Dacetuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dacetuzumab.	Investigational
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational, Withdrawn
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Dalotuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dalotuzumab.	Investigational
Daratumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Daratumumab.	Approved
Dasatinib	The risk or severity of adverse effects can be increased when Dasatinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Deflazacort	The risk or severity of adverse effects can be increased when Deflazacort is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Demcizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Demcizumab.	Investigational
Denosumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Denosumab.	Approved
Deoxyspergualin	The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Depatuxizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Depatuxizumab.	Investigational
Desonide	The risk or severity of adverse effects can be increased when Desonide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Desoxycorticosterone acetate	The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Vet Approved
Dexamethasone	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Vet Approved
Diflorasone	The risk or severity of adverse effects can be increased when Diflorasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Difluocortolone	The risk or severity of adverse effects can be increased when Difluocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Withdrawn
Difluprednate	The risk or severity of adverse effects can be increased when Difluprednate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Dinutuximab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Doxifluridine	The risk or severity of adverse effects can be increased when Doxifluridine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Dulaglutide	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dulaglutide.	Approved, Investigational
Duligotuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Duligotuzumab.	Investigational
Dupilumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dupilumab.	Approved, Investigational
Durvalumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Durvalumab.	Approved, Investigational
Dusigitumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dusigitumab.	Investigational
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Edrecolomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Edrecolomab.	Experimental, Investigational
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Eldelumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Eldelumab.	Investigational
Elotuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Elotuzumab.	Approved
Emibetuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Emibetuzumab.	Investigational
Emicizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Emicizumab.	Approved, Investigational
Enokizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enokizumab.	Investigational
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Epratuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Epratuzumab.	Investigational
Equilenin	The risk or severity of adverse effects can be increased when Equilenin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Equilin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Erenumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Erenumab.	Approved, Investigational
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Estrone	The risk or severity of adverse effects can be increased when Estrone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Etanercept	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Etanercept.	Approved, Investigational
Etanercept	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Etanercept.	Approved, Investigational
Etaracizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Etaracizumab.	Investigational
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Etrolizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Etrolizumab.	Investigational
Everolimus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Everolimus.	Approved
Everolimus	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Everolimus.	Approved
Evolocumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Evolocumab.	Approved
Farletuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Farletuzumab.	Investigational
Ficlatuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ficlatuzumab.	Investigational
Figitumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Figitumumab.	Investigational
Fingolimod	The risk or severity of adverse effects can be increased when Fingolimod is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Firategrast	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Firategrast.	Investigational
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Fluasterone	The risk or severity of adverse effects can be increased when Fluasterone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Flumethasone	The risk or severity of adverse effects can be increased when Flumethasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Fluocinonide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Fluocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Fluprednidene is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Fluticasone	The risk or severity of adverse effects can be increased when Fluticasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Experimental, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Fluticasone propionate	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Fluticasone propionate.	Approved
Fluticasone propionate	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fluticasone propionate.	Approved
Fontolizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fontolizumab.	Investigational
Formestane	The risk or severity of adverse effects can be increased when Formestane is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Withdrawn
Fremanezumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fremanezumab.	Investigational
Fresolimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fresolimumab.	Investigational
Fulranumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fulranumab.	Investigational
Galiximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Galiximab.	Investigational
Gallium nitrate	The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ganitumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ganitumab.	Investigational
Gantenerumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gantenerumab.	Investigational
Gemcitabine	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemcitabine.	Approved
Gemcitabine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gemcitabine.	Approved
Gemtuzumab ozogamicin	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin.	Approved, Investigational
Gemtuzumab ozogamicin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.	Approved, Investigational
Gevokizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gevokizumab.	Investigational
Glatiramer	The risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Glembatumumab vedotin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Glembatumumab vedotin.	Investigational
Golimumab	The risk or severity of adverse effects can be increased when Golimumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Gramicidin D	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gramicidin D.	Approved
GS 0573	The risk or severity of adverse effects can be increased when GS 0573 is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Guselkumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Guselkumab.	Approved, Investigational
Gusperimus	The risk or severity of adverse effects can be increased when Gusperimus is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Halcinonide	The risk or severity of adverse effects can be increased when Halcinonide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Withdrawn
HE3286	The risk or severity of adverse effects can be increased when HE3286 is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Human C1-esterase inhibitor	The risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Human cytomegalovirus immune globulin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Human cytomegalovirus immune globulin.	Approved
Human Varicella-Zoster Immune Globulin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.	Approved
Hydrocortisone	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Hydrocortisone.	Approved, Vet Approved
Hydrocortisone	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Hydrocortisone.	Approved, Vet Approved
Hydrocortisone acetate	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Hydrocortisone acetate.	Approved, Vet Approved
Hydrocortisone acetate	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Hydrocortisone acetate.	Approved, Vet Approved
Hydrocortisone butyrate	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Hydrocortisone butyrate.	Approved, Vet Approved
Hydrocortisone butyrate	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Hydrocortisone butyrate.	Approved, Vet Approved
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Hypericin	The risk or severity of adverse effects can be increased when Hypericin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Ibalizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ibalizumab.	Approved, Investigational
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ibrutinib	The risk or severity of adverse effects can be increased when Ibrutinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Idarucizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Idarucizumab.	Approved
Idelalisib	The risk or severity of adverse effects can be increased when Idelalisib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Ifosfamide	The risk or severity of adverse effects can be increased when Ifosfamide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
IGN311	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with IGN311.	Investigational
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
IMC-1C11	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with IMC-1C11.	Investigational
Imipenem	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Imipenem.	Approved
Imiquimod	The risk or severity of adverse effects can be increased when Imiquimod is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Inclacumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Inclacumab.	Investigational
Indium In-111 satumomab pendetide	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Indium In-111 satumomab pendetide.	Approved, Withdrawn
Inebilizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Inebilizumab.	Investigational
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Inotuzumab ozogamicin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Inotuzumab ozogamicin.	Approved, Investigational
Interferon alfa-n3	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-n3.	Approved, Investigational
Interferon alfa-n3	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Interferon alfa-n3.	Approved, Investigational
Intetumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Intetumumab.	Investigational
IPH 2101	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with IPH 2101.	Investigational
Ipilimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ipilimumab.	Approved
Iratumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Iratumumab.	Investigational
Irinotecan	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Irinotecan.	Approved, Investigational
Irinotecan	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Irinotecan.	Approved, Investigational
Istaroxime	The risk or severity of adverse effects can be increased when Istaroxime is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Ixekizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ixekizumab.	Approved, Investigational
L-Phenylalanine	The risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Nutraceutical
Labetuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Labetuzumab.	Investigational
Lampalizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lampalizumab.	Investigational
Landogrozumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Landogrozumab.	Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Lerdelimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lerdelimumab.	Investigational
Lexatumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lexatumumab.	Investigational
Ligelizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ligelizumab.	Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Lorvotuzumab mertansine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lorvotuzumab mertansine.	Investigational
Loteprednol	The risk or severity of adverse effects can be increased when Loteprednol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Lucatumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lucatumumab.	Investigational
Lumiliximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lumiliximab.	Investigational
Matuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Matuzumab.	Investigational
Mavrilimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mavrilimumab.	Investigational
ME-609	The risk or severity of adverse effects can be increased when ME-609 is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Medrysone	The risk or severity of adverse effects can be increased when Medrysone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Melengestrol	The risk or severity of adverse effects can be increased when Melengestrol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Vet Approved
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Meropenem	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Meropenem.	Approved, Investigational
Methimazole	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Methimazole.	Approved
Methimazole	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Methimazole.	Approved
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Methylprednisolone	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Methylprednisolone.	Approved, Vet Approved
Methylprednisolone	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Methylprednisolone.	Approved, Vet Approved
Milatuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Milatuzumab.	Investigational
Mirvetuximab Soravtansine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mirvetuximab Soravtansine.	Investigational
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Mogamulizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mogamulizumab.	Approved, Investigational
Mometasone	The risk or severity of adverse effects can be increased when Mometasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Vet Approved
Motavizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Motavizumab.	Investigational
Moxifloxacin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Moxifloxacin.	Approved, Investigational
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
MYO-029	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with MYO-029.	Investigational
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Naptumomab Estafenatox	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Naptumomab Estafenatox.	Investigational
Natalizumab	The risk or severity of adverse effects can be increased when Natalizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
NCX 1022	The risk or severity of adverse effects can be increased when NCX 1022 is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Nebacumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nebacumab.	Experimental
Necitumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Necitumumab.	Approved, Investigational
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Neomycin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Neomycin.	Approved, Vet Approved
Nilotinib	The risk or severity of adverse effects can be increased when Nilotinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Nimotuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nimotuzumab.	Investigational
Nivolumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nivolumab.	Approved
Nystatin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nystatin.	Approved, Vet Approved
Obiltoxaximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Obiltoxaximab.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ocrelizumab	The therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ofatumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ofatumumab.	Approved
Olaratumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Olaratumab.	Approved, Investigational
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Olokizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Olokizumab.	Investigational
Onartuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Onartuzumab.	Investigational
Oregovomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Oregovomab.	Investigational
Otelixizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Otelixizumab.	Investigational
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Ozanezumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ozanezumab.	Investigational
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Vet Approved
Palbociclib	The risk or severity of adverse effects can be increased when Palbociclib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Palivizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Palivizumab.	Approved, Investigational
Panitumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Panitumumab.	Approved, Investigational
Panobinostat	The risk or severity of adverse effects can be increased when Panobinostat is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Paquinimod	The risk or severity of adverse effects can be increased when Paquinimod is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Paramethasone	The risk or severity of adverse effects can be increased when Paramethasone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Paromomycin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Paromomycin.	Approved, Investigational
Patritumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Patritumab.	Investigational
Pazopanib	The risk or severity of adverse effects can be increased when Pazopanib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Pegaspargase	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Pegaspargase.	Approved, Investigational
Pegaspargase	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pegaspargase.	Approved, Investigational
Peginterferon alfa-2a	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Peginterferon alfa-2a.	Approved, Investigational
Peginterferon alfa-2a	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Peginterferon alfa-2a.	Approved, Investigational
Peginterferon alfa-2b	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Peginterferon alfa-2b.	Approved
Peginterferon alfa-2b	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Peginterferon alfa-2b.	Approved
Pembrolizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pembrolizumab.	Approved
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Pertuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pertuzumab.	Approved
Pexelizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pexelizumab.	Investigational
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Piperacillin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Piperacillin.	Approved
Pirarubicin	The risk or severity of adverse effects can be increased when Pirarubicin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Polatuzumab Vedotin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Polatuzumab Vedotin.	Investigational
Polymyxin B Sulfate	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Polymyxin B Sulfate.	Approved, Vet Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Pomalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Pralatrexate	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Prasterone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Prednicarbate is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Prednisolone	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Prednisolone.	Approved, Vet Approved
Prednisolone	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Pregnenolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Experimental, Investigational
PRO 140	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with PRO 140.	Investigational
PRO-542	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with PRO-542.	Investigational
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
R1507	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with R1507.	Investigational
Racotumomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Racotumomab.	Investigational
Ramucirumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ramucirumab.	Approved, Investigational
Ranibizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ranibizumab.	Approved
Raxibacumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Raxibacumab.	Approved
Reslizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Reslizumab.	Approved, Investigational
RI 624	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with RI 624.	Investigational
Rifampicin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rifampicin.	Approved
RIGScan CR49	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with RIGScan CR49.	Investigational
Rilonacept	The risk or severity of adverse effects can be increased when Rilonacept is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Rilotumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rilotumumab.	Investigational
Rimexolone	The risk or severity of adverse effects can be increased when Rimexolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Robatumumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Robatumumab.	Investigational
Romosozumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Romosozumab.	Investigational
Rontalizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rontalizumab.	Investigational
Ruxolitinib	The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Sacituzumab govitecan	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sacituzumab govitecan.	Investigational
Sarilumab	The risk or severity of infection can be increased when Sarilumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Secukinumab	The risk or severity of adverse effects can be increased when Secukinumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Semapimod	The risk or severity of adverse effects can be increased when Semapimod is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Seocalcitol	The risk or severity of adverse effects can be increased when Seocalcitol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental, Investigational
Seribantumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Seribantumab.	Investigational
Sibrotuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sibrotuzumab.	Investigational
Siltuximab	The risk or severity of adverse effects can be increased when Siltuximab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Silver sulfadiazine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Silver sulfadiazine.	Approved, Vet Approved
Siplizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Siplizumab.	Investigational
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Sirukumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sirukumab.	Investigational
Solanezumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Solanezumab.	Investigational
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Stepronin	The risk or severity of adverse effects can be increased when Stepronin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Sulesomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sulesomab.	Approved
Sulfasalazine	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Sulfasalazine.	Approved
Sulfasalazine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sulfasalazine.	Approved
Sunitinib	The risk or severity of adverse effects can be increased when Sunitinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
SYM001	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with SYM001.	Investigational
Tabalumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tabalumab.	Investigational
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Tanezumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tanezumab.	Investigational
Tarextumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tarextumab.	Investigational
Tazobactam	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tazobactam.	Approved
TB-402	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TB-402.	Investigational
Technetium Tc-99m arcitumomab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Technetium Tc-99m arcitumomab.	Approved, Investigational
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Temsirolimus is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Teplizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Teplizumab.	Investigational
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Vet Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Tetanus Immune Globulin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tetanus Immune Globulin.	Approved
Tetracycline	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tetracycline.	Approved, Vet Approved
Tetrandrine	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Tetrandrine.	Experimental
Tetrandrine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tetrandrine.	Experimental
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Withdrawn
Thiotepa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Tildrakizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tildrakizumab.	Approved, Investigational
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Tixocortol	The risk or severity of adverse effects can be increased when Tixocortol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Withdrawn
TNX-901	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TNX-901.	Investigational
Tocilizumab	The risk or severity of adverse effects can be increased when Tocilizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Tofacitinib	The risk or severity of adverse effects can be increased when Tofacitinib is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Tovetumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tovetumab.	Investigational
Trabectedin	The risk or severity of adverse effects can be increased when Trabectedin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Tralokinumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tralokinumab.	Investigational
Trastuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Trastuzumab.	Approved, Investigational
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
TRC105	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TRC105.	Investigational
Tremelimumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tremelimumab.	Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational, Nutraceutical
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Triptolide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Trofosfamide	The risk or severity of adverse effects can be increased when Trofosfamide is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Ulobetasol	The risk or severity of adverse effects can be increased when Ulobetasol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Ustekinumab	The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Vancomycin	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Vancomycin.	Approved
Vedolizumab	The risk or severity of adverse effects can be increased when Vedolizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Veltuzumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Veltuzumab.	Investigational
Vilanterol	The risk or severity of adverse effects can be increased when Vilanterol is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Visilizumab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Visilizumab.	Investigational
Voclosporin	The risk or severity of adverse effects can be increased when Voclosporin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Investigational
Volociximab	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Volociximab.	Investigational
Wortmannin	The risk or severity of adverse effects can be increased when Wortmannin is combined with Bacillus calmette-guerin substrain connaught live antigen.	Experimental
XmAb 2513	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with XmAb 2513.	Investigational
XTL-001	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with XTL-001.	Investigational
Zidovudine	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Zidovudine.	Approved
Zidovudine	The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Zidovudine.	Approved

Food Interactions

Not Available

References

General References

Not Available

External Links

PubChem Substance: 347910910

AHFS Codes

80:12.00 — Vaccines

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Recruiting	Treatment	Bladder Cancers	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intravesical	81 mg/3mL

Prices

Not Available

Patents

Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Taxonomy

Classification: Not classified

Drug created on December 01, 2015 13:04 / Updated on August 15, 2018 09:57